Please login to the form below
Valneva
This page shows the latest Valneva news and features for those working in and with pharma, biotech and healthcare.
Bavarian Nordic’s chikungunya vaccine candidate shows promise in late-stage trial
Valneva has its own chikungunya vaccine candidate in late-stage development, VLA1553. ... A Biologic License Application for Valneva’s candidate is currently under priority review by the US Food and Drug Administration, with a Prescription Drug User
Latest news
-
Valneva reports additional data for COVID-19 booster
Valneva has reported additional data from a small exploratory study of its COVID-19 booster vaccine, VLA2001, for people aged 18 years and older. ... Juan Carlos Jaramillo, Valneva’s chief medical officer, said: “While these latest booster results
-
Valneva’s chikungunya vaccine candidate shows promise in antibody persistence trial
Valneva’s chikungunya vaccine candidate, VLA1553, has shown promising 12-month antibody persistence results after a single-dose, the vaccine company reported. ... A dedicated antibody persistence trial, VLA1553-303, was set up by Valneva to confirm the
-
Pfizer and Valneva report six-month antibody persistence data for Lyme disease vaccine
Pfizer and Valneva have reported antibody persistence data six months after the completion of a three or two-dose vaccination schedule with their Lyme disease vaccine candidate, VLA15, in both children ... In August, Pfizer and Valneva announced they had
-
Valneva actively discussing second-generation COVID-19 vaccine with prospective partner
Valneva further expects to report additional clinical data in the fourth quarter of 2022, notably heterologous booster data, which may potentially support the positioning of its inventory. ... Valneva currently has agreements to supply VLA2001 to certain
-
WHO recommends Valneva’s COVID-19 vaccine for those aged between 18 to 50 years old
People aged 18 to 29 years old who received Valneva produced even more neutralising antibodies, following two doses of the vaccine. ... Initial results are available and indicate that the Valneva vaccine produces fewer neutralising antibodies against the
More from news
Approximately 21 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Pharma deals during December 2012
The Vivalis shareholders will own 55 per cent of the new company called Valneva based in Lyon and the Intercell shareholders will obtain a 32 per cent premium for their shares.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Valneva expands management board
Appoints David Lawrence and Wolfgang Bender. Commercial stage biotech Valneva has appointed David Lawrence and Wolfgang Bender, a move that will strengthen the senior management team for future growth.
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
